|
Novo Nordisk and Innate Pharma swap product rights |
|
Tuesday, 07 October 2008 |
Novo Nordisk A/S and Innate Pharma have reached an agreement by which Innate Pharma is granted development and commercialisation rights to NN1975/IPH 2101 in exchange for EUR 2.5 million upfront payment, milestone payments and royalties on future sales of IPH 2101. |
|
Read more...
|
|
|
Roche invests 215 million Swiss francs in diagnostics facility at Penzberg |
|
Thursday, 02 October 2008 |
Roche is investing 215 million Swiss francs (136 million euros) in research, development and production at its site in Penzberg, near Munich. The money will be used to construct a multi-purpose building for Roche Diagnostics. |
|
Read more...
|
|
|
Novo Nordisk acquires intellectual property rights from Neose Technologies |
|
Thursday, 18 September 2008 |
Novo Nordisk today announced that it has signed an agreement to acquire intellectual property rights from Neose Technologies Inc. related to Neose's proprietary GlycoPEGylation technology. The acquired rights are currently subject to a license from Neose for Novo Nordisk's development of GlycoPEGylated recombinant blood clotting factors FVIIa, FVIII and FIX. |
|
Read more...
|
|
|
Bayer HealthCare acquires German DIREVO Biotech AG |
|
Wednesday, 17 September 2008 |
Bayer HealthCare AG acquires the German biotech company DIREVO Biotech AG, Cologne. With the acquisition of the biotech company specialized in protein engineering, Bayer strengthens the research competence in biologicals of its pharmaceutical division Bayer Schering Pharma. |
|
Read more...
|
|
|
Alpharma Responds To Unsolicited Proposal By King Pharmaceuticals, Inc. |
|
Monday, 25 August 2008 |
|
Alpharma, Inc. (NYSE: ALO), a global specialty pharmaceutical company, confirmed that it received an unsolicited, non-binding proposal from King Pharmaceuticals, Inc. (NYSE: KG) to acquire all of the outstanding shares of Alpharma for $33.00 per share in cash. Alpharma said that proposal was identical in all material respects to two prior proposals made privately by King to the company. |
|
Read more...
|
|
|
King Proposes Acquisition of Alpharma for $33 Per Share in Cash |
|
Sunday, 24 August 2008 |
|
King Pharmaceuticals, Inc. (NYSE: KG) announced that it has submitted to the Board of Directors of Alpharma Inc. (NYSE: ALO) a proposal to acquire all of the outstanding shares of common stock of Alpharma for $33.00 per share in cash. The proposal is not conditioned on financing. |
|
Read more...
|
|
|
Nycomed - strong results in second quarter 2008 |
|
Tuesday, 19 August 2008 |
In the first six months of 2008, Nycomed’s adjusted EBITDA increased by 4.9% to € 653.7 million compared to € 623.3 million in the first six months of 2007, benefiting from the cost decreasing effects of last year’s restructuring and as a result of the successful integration. |
|
Read more...
|
|
|
Divestment of four Roche pharmaceutical products to Meda |
|
Friday, 15 August 2008 |
Roche and Meda, an international specialty pharmaceutical company based in Solna (Stockholm), Sweden, have signed an agreement for the sale of four Roche pharmaceutical products to Meda. The world wide product rights for Marcoumar (Anticoagulant), Torem (Loop diuretic), Tilcotil (painful musculoskeletal disorders) and Aurorix (Depression) are being transferred to Meda for a total amount of 120 million Euros. |
|
Read more...
|
|
|
Teva Reports Second Quarter 2008 Results - Record Quarterly Sales of $2,823 Million |
|
Wednesday, 13 August 2008 |
Net sales for the second quarter of 2008 increased 18 percent to $2,823 million, compared to $2,386 million in the second quarter of 2007. Net income for the second quarter of 2008 totaled $539 million, compared to $515 million for the same period of 2007 (up 5 percent), while diluted earnings per share increased to $0.65 from $0.63 (up 3 percent). |
|
Read more...
|
|
|
Boehringer Ingelheim continued to post strong growth in local currencies in the first half of 2008 |
|
Monday, 11 August 2008 |
The pharmaceutical company Boehringer Ingelheim continued to post strong growth in local currencies in the first half of 2008 (+9.0%). On account of the strength of the euro against the US dollar and the Japanese yen, growth after consolidation in euro was +2.1% with net sales of EUR 5,522 million compared with EUR 5,407 million in the first six months of 2007. |
|
Read more...
|
|
|
<< Start < Prev 1 2 3 4 5 6 7 8 Next > End >>
|
| Results 1 - 10 of 78 |